Nova Leap Health Corp. Announces Brokered Private Placement with Haywood Securities Inc.

HALIFAX, NOVA SCOTIA--(Marketwired - Jan. 19, 2018) -

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN

NOVA LEAP HEALTH CORP. (TSX VENTURE:NLH) ("Nova Leap" or the "Company"), is pleased to announce that it has appointed Haywood Securities Inc. (the "Agent"), to sell, by way of a private placement on a best efforts basis, units (the "Units") of the Company at a price of $0.25 per Unit (the "Issue Price") for gross proceeds of a minimum of $1,250,000 and maximum of $2,000,000 (the "Offering").

Each Unit issued pursuant to the Offering will consist of one common share in the capital of the Company (a "Common Share") and one half of one Common Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitles the holder thereof to purchase one additional Common Share at a price of $0.375 for a period of 24 months from the closing date of the Offering.

The Agent has been granted the option (the "Agent's Option") to sell up to an additional 2,000,000 Units at the Issue Price, exercisable in whole or in part at any time up to 48 hours prior to the closing of the Offering.

The Company intends to use the net proceeds of the Offering to partially fund the acquisition of the home care business located in the Northeastern United States as announced on January 9, 2018 and for working capital and general corporate purposes. The Company expects the remainder of the purchase price to be funded with debt from a Schedule 1 Canadian bank.

The Company will pay the Agent upon the closing of the Offering: 1) a cash commission equal to 8.0% of the gross proceeds of the Offering, except in respect of any subscriptions by purchasers for the Offering on the President's List, which will only have a cash commission equal to 2.0% of the gross proceeds from the sale of Units under the Offering; 2) broker warrants equal to 8.0% of the Units sold to purchasers not listed on the President's List and 2.0% of the number of Units sold to purchasers listed on the President's List; and 3) a corporate finance fee of $40,000, of which $20,000 shall be payable in cash, and $20,000 payable in common shares of the Company, subject to compliance with all required regulatory approvals. Each broker warrant shall be exercisable for one Common Share at a price of $0.25 for a period of 24 months following the closing date of the Offering.